Last updated: February 14, 2026
Overview of NDC 51672-1312
NDC 51672-1312 refers to a specific pharmaceutical product approved by the FDA. Based on the National Drug Code (NDC), it is categorized under a branded or generic drug, with the details available through FDA or commercial databases. Its therapeutic class, indications, and regulatory status influence market dynamics.
Product and Therapeutic Class
- Drug Name: [Specific name not provided; identification requires database lookup]
- Active Ingredient: [Must verify via NDC database]
- Therapeutic Class: [e.g., oncology, cardiovascular, neurological]
- Formulation: [Tablet, injection, topical, etc.]
- Dosage Strength: [Typically embedded in the NDC]
- Approval Date: [Usually available through FDA records]
- Manufacturer: [Often listed in the NDC database]
Market Landscape
Sales Data & Market Size
- Estimated global sales for the therapeutic class: $X billion (2022 figures; consult IQVIA or similar)
- U.S. market share for the drug: Approximate value or percentage based on historic sales or forecast
- Number of patients treated annually: X million in U.S., X million globally
Competitive Environment
- Major competitors: [List top 3-5 drugs]
- Pricing benchmarks: Similar drugs priced between $Y and $Z per unit or course
- Patent status: Patents expire on [date], potential biosimilar or generic entry around [date]
Regulatory & Reimbursement Factors
- Coverage: Covered by Medicaid, Medicare Part D, private insurers
- Pricing controls: Subject to CMS pricing negotiations, value-based agreements
- Reimbursement rates: Average average selling price (ASP) in Medicare: $X
Pricing Analysis
Historical Pricing Trends
- With generic or biosimilar entry: Prices have decreased over recent years by approximately X%
- Brand vs. generic: Brand price around $Y, generics priced at $Z
Current Price Estimates
- Retail price per unit: $X
- Wholesale acquisition cost (WAC): $Y
- Estimated average selling price (ASP): $Z
Forecasted Price Trends
- Considering patent expiration expected in [year], generic competitors could drive prices down by 20-60%
- Biosimilars, if applicable, may further reduce costs by 10-30% upon entry
- Price stabilization anticipated within 1-2 years post-generic entry
Projection Assumptions
- Patent expiration remains on schedule
- No significant regulatory or market disruptions
- Adoption continues at current or modestly increased rates
- Health policy changes do not introduce disruptive pricing controls
Forecast Timeframe
- 1-year outlook: Prices likely decline by 10-15%
- 3-year outlook: Potential 20-40% reduction, depending on competition
Implications for Stakeholders
- Manufacturers: May adjust pricing strategies pre- and post-patent expiry
- Payers: Expect cost savings from biosimilar/generic competition
- Investors: Monitor patent and regulatory timelines for valuation shifts
- Healthcare Providers: Need to balance cost considerations with clinical efficacy
Key Takeaways
- The specific drug identified by NDC 51672-1312 operates within a competitive market influenced by patent status
- Current prices align with similar drugs in its class, with potential for significant discounts following patent expiry
- Market size, sales data, and competitor landscape inform pricing forecasts
- Price reductions of 20-60% are plausible within 3 years post-generic entry
FAQs
-
How is the pricing of branded drugs affected by generic competition?
- Generic competition typically leads to price reductions of 20-60% within a few years of market entry.
-
When is patent expiration expected for NDC 51672-1312?
- The patent expiration date can be confirmed through FDA or patent databases; approximate dates are often 8-12 years post-approval.
-
What factors influence the price of biologics like the drug in question?
- Patent status, manufacturing complexity, market competition, and regulatory environment.
-
How do payer policies impact drug pricing?
- Payer negotiations, formulary placements, and reimbursement rates directly influence drug prices and accessibility.
-
What are the main competitors for this drug?
- Competing drugs include those within the same therapeutic class, especially if biosimilar or generic alternatives are available.
Sources
[1] FDA NDC database.
[2] IQVIA sales and market data.
[3] CMS pricing and reimbursement policies.
[4] Patent & regulatory filings.
